Transcode Therapeutics, Inc. (RNAZ): Insider Trading, Congress Trades & Research | Tormere

RNAZ

$1.60+1.91%visit website

Transcode Therapeutics, Inc.

Market Cap

$30M

Finnhub, as of 2026-09-22

Sector

Health Care

Industry

Biotechnology

Beta (raw)

1.24

52mo monthly vs SPY

P/E (TTM)

—

Price / TTM diluted EPS

P/S (TTM)

—

Mkt cap / TTM revenue

P/B

—

Mkt cap / shareholders' equity

EV/EBITDA (TTM)

—

EV / TTM EBITDA

Loading…

Financial Statements

USD thousands	Q3 FY2025 Sep 30, 2025	Q4 FY2025 Dec 31, 2025	Q1 FY2026 Mar 31, 2026	Q2 FY2026 Jun 30, 2026	TTM Jun 30, 2026
Research & development	3,161	5,475	5,107	3,694	17,437
Total operating expenses	4,561	16,027	17,755	6,790	45,132
Operating income	(4,561)	(16,027)	(17,755)	(6,790)	(45,132)
Interest expense	5.96	0.54
Pretax income			(17,554)	(6,750)
Income tax	0	226
Net income	(4,856)	(13,443)	(17,785)	(6,750)	(42,834)
EPS (basic) ($)	(5.82)		(21.28)	(7.17)	—
EPS (diluted) ($)	(5.82)		(21.28)	(7.17)	—
Weighted avg. shares (basic)	834		917	957
Weighted avg. shares (diluted)	834		917	957

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Aug 14, 2026, period ended Jun 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 21 more quarters, back to Jun 2020, with Tormere Pro.

Signals

Insider Velocity

no recent activity

purchases / sales, 90d

Market & Alt Data

News

15

recent articles

CK Life Sciences Intl (Holdings) Inc · 2026-08-03

No Form 4 transactions on record.

Recent News

RNAZ Stock Price, Quote & News

Syfe · 2026-10-30

TransCode Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process Intended to Maximize Value of TTX-MC138 and its Oncology Portfolio

Yahoo · 2026-10-28

An experimental cancer treatment could be licensed or sold as TransCode weighs options

Stock Titan · 2026-10-28

TransCode Therapeutics' Board Initiates A Formal Strategic Process To Evaluate Opportunities Designed To Maximize The Value Of The Company And Its Oncology Portfolio, Including Its Lead Product Candidate, TTX-MC138

Benzinga · 2026-10-28

TransCode Therapeutics Presents Phase 1a Clinical Data for TTX-MC138 at ESMO Congress 2026

Yahoo · 2026-10-26

The cancer treatment showed exploratory signs of immune activity against tumors.

Stock Titan · 2026-10-26

Natera Partners With TransCode to Advance Colorectal Cancer Trial

Yahoo · 2026-10-21

TransCode Therapeutics to Present Phase 1a Clinical Trial Data for TTX-MC138 at ESMO Congress 2026

Yahoo · 2026-10-19

TransCode Therapeutics To Present Poster Featuring TTX-MC138 ESMO Congress 2026

Benzinga · 2026-10-19

TransCode Therapeutics (RNAZ) Ticks Higher: Shares Gain 2.98% to Close at $1.73 - Double EMA

https://www.siam.in/ · 2026-10-15

Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer

Yahoo · 2026-10-13

Natera, TransCode Therapeutics Partnering To Support Enrollment For TransCode’s Phase 2a Study Of TTX-MC138 In Participants With Colorectal Cancer

Benzinga · 2026-10-13

TransCode Therapeutics Announces Patent Advancements in Australia and Japan Strengthening Global IP Position in RNA-Based Immuno-Oncology

Yahoo Finance · 2026-09-22

Join Today's Live Investor Webinar with TransCode Therapeutics

Yahoo Finance · 2026-09-16

TransCode Therapeutics Announces Leadership Transition

Yahoo Finance · 2026-09-10

Informational purposes only, not investment advice.